# US 2012/0252867 A1 · Method of therapy and diagnosis of atherosclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252867 A1
- Document ID: US20120252867A1
- Status: Published application
- Kind: A1
- Application number: 13/152,520
- Filed: 2011-06-03
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Kaoshiung Medical University
- Inventors: Suh-Hang JUO; Ku-Chugn Chen; I-Chung Hsieh; Ching-Yu Hu
- Web page: https://patentgrep.com/patent/US20120252867A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/323: Arteriosclerosis, Stenosis
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

## Claims

### Claim 1

A method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), as well as the binding of lectin-like oxidized low density lipoprotein receptor-1 and oxidized low-density lipoprotein (oxLDL).

### Claim 2

An active substance of medication for atherosclerosis comprising microRNA let-7g, an analogue thereof or modified let-7g.

### Claim 3 (depends on 2)

The active substance of medication for atherosclerosis as defined in claim 2, further comprising at least one of drug acceptable excipient, carrier substrate and other ingredients.

### Claim 4

A method of diagnosis of atherosclerosis, comprising determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

### Claim 5 (depends on 4)

The method of diagnosis of atherosclerosis as defined in claim 4, wherein the levels of microRNA let-7g is determined by quantitative real time polymerase chain reaction, northern blotting assay, or miRNA microarray.

### Claim 6 (depends on 4)

The method of diagnosis of atherosclerosis as defined in claim 4, wherein the microRNA let-7g is determined as a diagnostic marker of atherosclerosis.
